Pharmacokinetics and bioavailability of intranasal fluticasone in humans

Clinical Drug Investigation

Volumn 14, Issue 1, 1997, Pages 44-52

  McDowall, J E ^a   Mackie, A E ^a   Ventresca, G P ^a   Bye, A ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; FLUTICASONE PROPIONATE; HYDROCORTISONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INTRANASAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SINGLE BLIND PROCEDURE;

EID: 0030855344     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199714010-00006     Document Type: Article

References (15)

1. Howarth PH. The immunopharmacology of rhinitis. In: Mackay IS, editor. Rhinitis, mechanisms and management. London, New York: Royal Society of Medicine Services Ltd, 1989: 33-51
2. Mackay IS. Topical medical management of allergic conditions of the nose. Pt 2: Intranasa steroids. In: Mackay IS, editor. Rhinitis, mechanisms and management. London, New York: Royal Society of Medicine Services Ltd, 1989; 183-98
3. Phillipps H. Structure-activity relationships of topically active steroids: the selection of fluticasone propionate. Respir Med 1990; 84: 19-23
4. Meltzer ED, Orgel HA, Bronsky EA, et al. A dose-ranging study of fluticasone propionate aqueous nasal spray for seasonal allergic rhinitis assessed by symptoms, rhinomanometry and nasal cytology. J. Allergy Clin Immunol 1990; 86: 221-30
5. Nathan RA, Bronsky EA, Fireman P, et al. Once daily fluticasone propionate aqueous nasal spray is an effective treatment for seasonal allergic rhinitis. Ann Allergy 1991; 67: 332-8
6. Ventresca GP, Mackie AE, Moss JA, et al. Absorption of oral fluticasone propionate in healthy subjects. Am J Respir Crit Care Med 1994; 149: A214
7. Falcoz C, Mackie AE, McDowall J, et al. Oral bioavailability of fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1996; 41: 459P-460P
8. McDowall JE, Mackie AE, Bye A, et al. Very low systemic exposure to intranasal fluticasone propionate. J Allergy Clin Immunol 1995; 51: A213
9. Bain BM, Harrison G, Jenkins KD, et al. A sensitive radioimmunoassay, incorporating solid-phase extraction, for fluticasone 17-propionate in plasma. J Pharm Biomed Anal 1993; 11: 557-61
10. Ayres JG, Bateman ED, Lundback B, et al. High dose fluticasone propionate, 1mg daily versus fluticasone propionate, 2mg daily, or budesonide 1.6mg daily, in patients with chronic severe asthma. Eur Respir J 1995; 8: 579-86
11. Fuller R, Johnson M, Bye A. Fluticasone propionate - an update on preclinical and clinical experience. Respir Med 1995; 89 Suppl. A: 3-18
12. Masuyama K, Jacobson MR, Rak S, et al. Topical glucocorticoid (fluticasone propionate) inhibits cells expressing mRNA for interleukin-4 in the nasal mucosa in allergen-induced rhinitis. Immunology 1994; 82: 192-9
13. Mackie AE, Ventresca GP, Fuller RW, et al. Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1996; 41: 539-42
14. Edsbacker S, Andersson K-E, Ryerfeldt A. Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man. Eur J Clin Pharmacol 1985; 29: 477-81
15. Pakes GK, Brogden RN, Heel RC, et al. Flunisolide: a review of its pharmacological properties and therapeutic efficacy in rhinitis. Drugs 1980; 19: 397-411